- Browse by Author
Browsing by Author "House, Michael"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Aberrant cholesterol metabolism in colorectal cancer represents a targetable vulnerability(Elsevier, 2023-07) Xie, Jingwu; Nguyen, Chi Mai; Turk, Anita; Nan, Hongmei; Imperiale, Thomas F.; House, Michael; Huang, Kun; Su, Jing; Biostatistics, School of Public HealthItem A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer(Elsevier, 2017-05-01) Lai, Xianyin; Wang, Mu; Deitz McElyea, Samantha; Sherman, Stuart; House, Michael; Korc, Murray; Department of Biochemistry & Molecular Biology, IU School of MedicinePancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy that often presents clinically at an advanced stage and that may be confused with chronic pancreatitis (CP). Conversely, CP may be misdiagnosed as PDAC leading to unwarranted pancreas resection. Therefore, early PDAC diagnosis and clear differentiation between PDAC and CP are crucial for improved care. Exosomes are circulating microvesicles whose components can serve as cancer biomarkers. We compared exosomal glypican-1 (GPC1) and microRNA levels in normal control subjects and in patients with PDAC and CP. We report that exosomal GPC1 is not diagnostic for PDAC, whereas high exosomal levels of microRNA-10b, (miR-10b), miR-21, miR-30c, and miR-181a and low miR-let7a readily differentiate PDAC from normal control and CP samples. By contrast with GPC1, elevated exosomal miR levels decreased to normal values within 24 h following PDAC resection. All 29 PDAC cases exhibited significantly elevated exosomal miR-10b and miR-30c levels, whereas 8 cases had normal or slightly increased CA 19-9 levels. Thus, our exosomal miR signature is superior to exosomal GPC1 or plasma CA 19-9 levels in establishing a diagnosis of PDAC and differentiating between PDAC and CP.Item Novel Preoperative Patient-centered Surgical Wellness Program Impacts Length of Stay Following Pancreatectomy(International Institute of Anticancer Research, 2021-04) Soufi, Mazhar; Deperalta, Danielle K.; Simpson, Rachel; Flick, Katelyn; Yip-Schneider, Michele T.; Schmidt, Christian M., II; Kilbane, Molly; Colgate, Cameron; Kelley, Kristen E.; Wooden, William; Ceppa, Eugene P.; House, Michael; Zyromski, Nicholas; Nakeeb, Atilla; Schmidt, C. Max; Surgery, School of MedicineBackground/Aim: We created a novel, preoperative wellness program (WP) that promotes recovery. This study assessed its impact on patient outcomes after pancreatectomy. Patients and Methods: Pancreatoduodenectomies (PD) and distal pancreatectomies (DP) performed from 2015 to 2018 were reviewed using our institutional NSQIP database. Patients in the WP had their medical conditions optimized and were provided with the following: chlorhexidine, topical mupirocin, incentive spirometer, and immune-nutrition supplements. Results: Out of a total of 669 pancreatectomy patients (411 PD, 258 DP), 308 were enrolled in the WP (188 PD, 120 DP). In the PD subgroup, on multivariable analysis (MVA), the WP patients had shorter lengths of hospital stay (LOS) (12 vs. 10 days, p<0.001). On MVA, WP patients had less post-op transfusion (20 vs. 10%, p=0.027). For the combined groups on MVA, LOS continued to be significant (OR=0.89, 95%CI=0.82-0.97, p<0.007). Conclusion: A preoperative patient centered WP may reduce the length of stay.